Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients

First-line use of tepotinib in METex14 NSCLC: A patient-centered journey

Non-covalent BTK inhibitor pirtobrutinib shows promise as frontline therapy for CLL/SLL

Linvoseltamab monotherapy in newly diagnosed multiple myeloma shows impressive frontline responses

Pimicotinib in TGCT demonstrates durable responses and sustained functional improvement

Latest in bladder cancer from the second half of 2025

Optimal management of gastric cancers

I-DXd shows strong brain metastasis responses in extensive-stage small cell lung cancer with manageable safety

Tarlatamab for SCLC: Subgroup analysis shows benefit regardless of previous chemo or anti-PD-(L)1 use

Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo

Temab-A plus bevacizumab shows promising response rates in advanced colorectal cancer